Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTA101 in relapsed or refractory diffuse large B-cell lymphoma
NCT04026100Phase 1Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2019
- Primary completion
- Aug 2022
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CTA101 in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
CTA101
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04026100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04026100.